

Psilocybin Propagation Committee Bylaws

Draft: 01-09-2026

Article I. Name

The name of this committee shall be the Psilocybin Propagation Committee (“the Committee”).

Article II. Authority

The Committee is established by and operates under the authority of the Medical Psilocybin Advisory Board (“the Board”) and serves in an advisory capacity only. All recommendations of the Committee are subject to review, modification, and adoption by the Board.

Article III. Purpose

The purpose of the Committee is to develop evidence informed, safety focused, and affordability conscious recommendations related to the cultivation, production, processing, testing, and quality assurance of psilocybin used in New Mexico’s medical psilocybin program.

The Committee’s work is intended to support patient safety, product quality and consistency, and reasonable cost for qualified patients and program participants.

Article IV. Scope of Responsibilities

The Committee shall carry out the following responsibilities:

1. Recommend best practices for psilocybin mushroom cultivation, harvesting, drying, storage, and contamination control standards
2. Recommend licensure criteria for producers, manufacturers, and laboratories.
3. Recommending to the full board rules on production, purity, potency, labeling, and packaging standards.
4. Monitor national and international research on product safety and testing innovations; recommend updates as needed.
5. Ensuring testing recommendations are as affordable as possible while requiring measures necessary for patient safety.

Article V. Committee Membership

1. Committee members shall be those individuals who attend and participate in the meeting.
2. Membership may include individuals with expertise in mycology, agriculture, cultivation, manufacturing, laboratory science, medicine, public health, regulatory compliance, or related and supporting disciplines.
3. Public members may be included, where appropriate, including but not limited to individuals with lived experience in agricultural production, small business operations, patient advocacy, or related areas.
4. Out-of-state participants may attend and speak at meetings; however, they will neither count for the quorum nor have voting rights.
5. Individuals who are disruptive during meetings may be removed from the meeting at the discretion of the Chair and may be prohibited from participating in future meetings.
6. Any individual voting needs to express conflict of interest during a vote on the request of the Chair.

Article VI. Chair and Leadership

1. The Committee Chair shall be appointed by the Chair of the Board.
2. The Chair is responsible for:
 - a. Convening and presiding over Committee meetings;
 - b. Setting meeting agendas in coordination with Board leadership and staff;
 - c. Ensuring timely development and submission of Committee recommendations;
 - d. Serving as the primary liaison between the Committee and the Board.

Article VII. Meetings

1. The Committee shall meet at the call of the Chair.
2. Meetings may be held in person, virtually, or in a hybrid format, subject to applicable open meetings and public-notice requirements.
3. Actions and recommendations of the Committee shall be approved by a majority vote of members present, unless otherwise specified by Board policy.

Article VIII. Voting and Recommendations

1. The Committee may adopt recommendations by majority vote of members present at a meeting. A quorum requires at least six members and the Committee Chair or their representative. Out-of-state participants may attend and speak at meetings; however, they will neither count for the quorum nor have voting rights.
2. All recommendations shall be documented in writing and transmitted to the Board for consideration.
3. Committee recommendations are advisory and shall not have binding effect unless adopted by the Board.

Article IX. Amendments

These bylaws may be amended by the Board upon recommendation of the Committee or at the Board's discretion.